stockrow
Saturday 7 November 2026
Export RDGT’s income statement to Excel — free account
Ridgetech Inc.
RDGT Healthcare Pharmaceutical Retailers
Ridgetech Inc.’s revenue for fiscal 2026 (year ended March 2026) was $132.2 million, up 10.2% from fiscal 2025.
1.00
0.25
+33.33%
Follow RDGT
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to March
| Ten-year view | Analyst estimates Powerpack | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Trend | 10 yrs | 2027e | 2028e | 2029e | Next 3/yr |
| Income, $m | |||||||||||||||||
| Income, $m | Revenue | 81 | 96 | 108 | 117 | 133 | 164 | 149 | 124 | 120 | 132 | +5.5% | — | — | — | — | |
| Gross margin, % | 20.40 | 20.94 | 23.35 | 21.76 | 21.97 | 22.21 | 23.04 | 3.93 | 3.20 | 3.60 | (16.8) pt | ||||||
| EBT | (6) | (17) | (1) | (6) | (8) | (2) | (21) | (1) | (1) | (1) | (14.6%) | ||||||
| EBT margin, % | (6.82) | (17.67) | (1.10) | (5.49) | (6.27) | (1.28) | (13.94) | (0.67) | (0.79) | (1.02) | +5.8 pt | ||||||
| Net income | (6) | (17) | (1) | (6) | (8) | (3) | (21) | (4) | 10 | (1) | (15.4%) | ||||||
| Per share, $ | |||||||||||||||||
| Per share, $ | Revenue | 135,831.83 | 137,303.86 | 134,438.75 | 130,364.11 | 121,031.45 | 567.07 | 14.59 | 12,782.90 | 3,242.48 | 1,817.93 | (38.1%) | |||||
| Earnings | (10,033.86) | (24,367.96) | (1,075.06) | (6,450.34) | (7,167.05) | (11.01) | (2.07) | (437.31) | 274.63 | (17.21) | (50.7%) | ||||||
| Cash flow | 2,599.17 | (2,957.29) | (7,004.00) | (7,675.44) | (56.64) | (18.58) | (0.32) | (325.30) | 33.72 | (19.17) | n/m | ||||||
| Capex | (685.33) | (4,145.71) | (9,136.37) | (2,537.56) | (549.27) | 0.00 | 0.00 | (95.23) | (16.63) | (0.01) | (72.8%) | ||||||
| Free cash flow | 1,913.83 | (7,103.00) | (16,140.37) | (10,213.00) | (605.91) | (18.58) | (0.32) | (420.53) | 17.09 | (19.18) | n/m | ||||||
| Book value | 44,440.67 | 26,946.29 | 21,214.00 | 20,864.56 | 22,184.00 | 83.08 | 1.77 | 1,473.52 | 800.98 | 560.89 | (38.5%) | ||||||
| Shares, m | 0 | 0 | 0 | 0 | 0 | 0 | 10 | 0 | 0 | 0 | +70.4% | ||||||
| Valuation, × | |||||||||||||||||
| Valuation, × | P/E | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | 0.48 | 0.34 | 0.76 | 0.50 | 0.42 | 0.07 | 0.06 | 0.00 | 0.00 | 0.00 | 0.3 | ||||||
| P/B | 1.46 | 1.75 | 4.84 | 3.12 | 2.27 | 0.65 | 1.02 | 0.04 | 0.01 | 0.00 | 1.5 | ||||||
| EV/Sales | 0.14 | 0.02 | 0.53 | 0.29 | 0.19 | (0.06) | (0.03) | (0.08) | (0.09) | (0.04) | 0.1 | ||||||
| EV/FCF | 9.76 | (0.23) | (4.02) | (3.69) | (37.48) | 2.72 | 0.94 | 2.88 | 2.93 | (1.33) | (2.8) | ||||||
| Cash, $m | |||||||||||||||||
| Cash, $m | Operating cash flow | 2 | (2) | (6) | (7) | 0 | (5) | (3) | (3) | 1 | (1) | n/m | |||||
| Capex | 0 | (3) | (7) | (2) | (1) | 0 | 0 | (1) | (1) | 0 | (53.7%) | ||||||
| Free cash flow | 1 | (5) | (13) | (9) | (1) | (5) | (3) | (4) | 1 | (1) | n/m | ||||||
| Balance, $m | |||||||||||||||||
| Balance, $m | Working capital | 16 | 8 | 1 | 4 | 7 | 1 | (2) | (5) | 25 | 37 | +9.7% | |||||
| Net debt | (15) | (12) | 1 | (25) | (30) | (35) | (32) | (4) | (19) | (18) | +1.8% | ||||||
| Shareholders’ equity | 27 | 19 | 17 | 19 | 24 | 24 | 18 | 14 | 30 | 41 | +4.8% | ||||||
| Returns, % | |||||||||||||||||
| Returns, % | ROA | (8.73) | (24.20) | (1.26) | (6.75) | (7.89) | (3.00) | (21.42) | (4.55) | 12.78 | (1.87) | +6.9 pt | |||||
| ROIC | (21.69) | (160.14) | (3.04) | 0.00 | 0.00 | 0.00 | 0.00 | 3.72 | (5.83) | (5.10) | +16.6 pt | ||||||
| ROE | (24.55) | (74.94) | (5.17) | (32.52) | (37.61) | (13.17) | (100.42) | (26.21) | 46.41 | (3.55) | +21.0 pt | ||||||
| People | |||||||||||||||||
| People | Employees | 893 | 1,139 | 1,079 | 1,074 | 1,047 | — | — | — | 61 | 64 | (25.4%) | |||||
| Revenue/emp, $m | 0.09 | 0.08 | 0.10 | 0.11 | 0.13 | 0.00 | 0.00 | 0.00 | 1.97 | 2.07 | +41.4% | ||||||
Negative figures in brackets.
estimates
Fiscal years to Mar 2026 · latest quarter Mar 2021 · fundamentals updated 26 Oct 2026
Ridgetech Inc. vs peers in Pharmaceutical Retailers (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| HITI High Tide Inc. | $234.4M | — (loss-making) | 23.4× | +30.72% (above 0%: growing) | +800.00% (above 0%: growing) | −7.91% (below 0%: shrinking) | 26.53% | 4.38% | Compare |
| PETS PetMed Express, Inc. | $26.9M | — (loss-making) | — (loss-making) | −19.86% (below 0%: shrinking) | n/m | +38.60% (above 0%: growing) | 27.63% | (15.19%) | Compare |
| POM Pomdoctor Limited - Sponsored ADR | $11.6M | — | — | — | — | — | — | — | Compare |
| SCNX Scienture Holdings, Inc. | $5.1M | — (loss-making) | — (loss-making) | +3,235.92% (above 0%: growing) | n/m | −53.98% (below 0%: shrinking) | 97.73% | (785.71%) | Compare |
| RDGT Ridgetech Inc. | $2.7M | — (loss-making) | — (loss-making) | +113.14% (above 0%: growing) | n/m | +4,848.31% (above 0%: growing) | 22.81% | 0.00% | |
| Median of peers | $19.2M | — | — | +30.72% | — | −7.91% | 27.63% | (15.19%) |